Differential effect of age on survival in advanced NSCLC in women versus men: Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab

H. A. Wakelee; S. E. Dahlberg; J. R. Brahmer; J. H. Schiller; M. C. Perry; C. J. Langer; A. B. Sandler; C. P. Belani; D. H. Johnson

doi:10.1016/j.lungcan.2011.12.006

Differential effect of age on survival in advanced NSCLC in women versus men: Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab

H. A. Wakelee, S. E. Dahlberg, J. R. Brahmer, J. H. Schiller, M. C. Perry, C. J. Langer, A. B. Sandler, C. P. Belani, D. H. Johnson

Research output: Contribution to journal › Article › peer-review

31 Scopus citations

Abstract

Background: The impact of age on prognosis in advanced stage non-small cell lung cancer (NSCLC) may differ by sex. Patients and methods: Eligible patients (N= 1590) from E1594, a 4-arm platinum-based chemotherapy trial, and E4599 (carboplatin/paclitaxel ± bevacizumab) chemotherapy arm were divided into male and female cohorts and separated into age groups of <60 or ≥60 years old. Eligible E4599 patients (N= 850) were similarly separated by age and sex and by treatment (±bevacizumab). Survival was calculated separately for each cohort. Results: The median survival time (MST) for women ≥60 years old treated with chemotherapy alone on E1594 and E4599 was 11.6 months versus 9.0 months for women <60 (p= 0.03). MST was 7.4 and 8.3 months for men ≥60 and <60 years old respectively (NS). In E4599 the age <60 by bevacizumab treatment interaction was statistically significant (p= 0.03) for women (younger had greater benefit), with no age effect in men. Conclusions: In this unplanned, exploratory subgroup analysis of advanced stage NSCLC ECOG trials, women ≥60 years old treated with chemotherapy live longer than men and younger women. In contrast, bevacizumab survival benefit was more pronounced in men of any age and in younger women on E4599.

Original language	English (US)
Pages (from-to)	410-415
Number of pages	6
Journal	Lung Cancer
Volume	76
Issue number	3
DOIs	https://doi.org/10.1016/j.lungcan.2011.12.006
State	Published - Jun 2012

Keywords

Age/sex interactions
Bevacizumab
Chemotherapy
NSCLC
Prognostic factors
Sex/gender differences

ASJC Scopus subject areas

Oncology
Pulmonary and Respiratory Medicine
Cancer Research

Access to Document

10.1016/j.lungcan.2011.12.006

Cite this

Wakelee, H. A., Dahlberg, S. E., Brahmer, J. R., Schiller, J. H., Perry, M. C., Langer, C. J., Sandler, A. B., Belani, C. P., & Johnson, D. H. (2012). Differential effect of age on survival in advanced NSCLC in women versus men: Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab. Lung Cancer, 76(3), 410-415. https://doi.org/10.1016/j.lungcan.2011.12.006

Wakelee, HA, Dahlberg, SE, Brahmer, JR, Schiller, JH, Perry, MC, Langer, CJ, Sandler, AB, Belani, CP & Johnson, DH 2012, 'Differential effect of age on survival in advanced NSCLC in women versus men: Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab', Lung Cancer, vol. 76, no. 3, pp. 410-415. https://doi.org/10.1016/j.lungcan.2011.12.006

@article{90a6b551cd364acebf6fdb4c09fbd02c,

title = "Differential effect of age on survival in advanced NSCLC in women versus men: Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab",

abstract = "Background: The impact of age on prognosis in advanced stage non-small cell lung cancer (NSCLC) may differ by sex. Patients and methods: Eligible patients (N= 1590) from E1594, a 4-arm platinum-based chemotherapy trial, and E4599 (carboplatin/paclitaxel ± bevacizumab) chemotherapy arm were divided into male and female cohorts and separated into age groups of <60 or ≥60 years old. Eligible E4599 patients (N= 850) were similarly separated by age and sex and by treatment (±bevacizumab). Survival was calculated separately for each cohort. Results: The median survival time (MST) for women ≥60 years old treated with chemotherapy alone on E1594 and E4599 was 11.6 months versus 9.0 months for women <60 (p= 0.03). MST was 7.4 and 8.3 months for men ≥60 and <60 years old respectively (NS). In E4599 the age <60 by bevacizumab treatment interaction was statistically significant (p= 0.03) for women (younger had greater benefit), with no age effect in men. Conclusions: In this unplanned, exploratory subgroup analysis of advanced stage NSCLC ECOG trials, women ≥60 years old treated with chemotherapy live longer than men and younger women. In contrast, bevacizumab survival benefit was more pronounced in men of any age and in younger women on E4599.",

keywords = "Age/sex interactions, Bevacizumab, Chemotherapy, NSCLC, Prognostic factors, Sex/gender differences",

author = "Wakelee, {H. A.} and Dahlberg, {S. E.} and Brahmer, {J. R.} and Schiller, {J. H.} and Perry, {M. C.} and Langer, {C. J.} and Sandler, {A. B.} and Belani, {C. P.} and Johnson, {D. H.}",

note = "Funding Information: This study was coordinated by the Eastern Cooperative Oncology Group (Robert L. Comis, M.D., Chair) and supported in part by Public Health Service Grants CA23318, CA66636, CA21115, CA16116, CA21076, CA15488, CA27252, CA49957 , and from the National Cancer Institute, National Institutes of Health and the Department of Health and Human Services . Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute. ",

year = "2012",

month = jun,

doi = "10.1016/j.lungcan.2011.12.006",

language = "English (US)",

volume = "76",

pages = "410--415",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd",

number = "3",

}

TY - JOUR

T1 - Differential effect of age on survival in advanced NSCLC in women versus men

T2 - Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab

AU - Wakelee, H. A.

AU - Dahlberg, S. E.

AU - Brahmer, J. R.

AU - Schiller, J. H.

AU - Perry, M. C.

AU - Langer, C. J.

AU - Sandler, A. B.

AU - Belani, C. P.

AU - Johnson, D. H.

N1 - Funding Information: This study was coordinated by the Eastern Cooperative Oncology Group (Robert L. Comis, M.D., Chair) and supported in part by Public Health Service Grants CA23318, CA66636, CA21115, CA16116, CA21076, CA15488, CA27252, CA49957 , and from the National Cancer Institute, National Institutes of Health and the Department of Health and Human Services . Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.

PY - 2012/6

Y1 - 2012/6

N2 - Background: The impact of age on prognosis in advanced stage non-small cell lung cancer (NSCLC) may differ by sex. Patients and methods: Eligible patients (N= 1590) from E1594, a 4-arm platinum-based chemotherapy trial, and E4599 (carboplatin/paclitaxel ± bevacizumab) chemotherapy arm were divided into male and female cohorts and separated into age groups of <60 or ≥60 years old. Eligible E4599 patients (N= 850) were similarly separated by age and sex and by treatment (±bevacizumab). Survival was calculated separately for each cohort. Results: The median survival time (MST) for women ≥60 years old treated with chemotherapy alone on E1594 and E4599 was 11.6 months versus 9.0 months for women <60 (p= 0.03). MST was 7.4 and 8.3 months for men ≥60 and <60 years old respectively (NS). In E4599 the age <60 by bevacizumab treatment interaction was statistically significant (p= 0.03) for women (younger had greater benefit), with no age effect in men. Conclusions: In this unplanned, exploratory subgroup analysis of advanced stage NSCLC ECOG trials, women ≥60 years old treated with chemotherapy live longer than men and younger women. In contrast, bevacizumab survival benefit was more pronounced in men of any age and in younger women on E4599.

AB - Background: The impact of age on prognosis in advanced stage non-small cell lung cancer (NSCLC) may differ by sex. Patients and methods: Eligible patients (N= 1590) from E1594, a 4-arm platinum-based chemotherapy trial, and E4599 (carboplatin/paclitaxel ± bevacizumab) chemotherapy arm were divided into male and female cohorts and separated into age groups of <60 or ≥60 years old. Eligible E4599 patients (N= 850) were similarly separated by age and sex and by treatment (±bevacizumab). Survival was calculated separately for each cohort. Results: The median survival time (MST) for women ≥60 years old treated with chemotherapy alone on E1594 and E4599 was 11.6 months versus 9.0 months for women <60 (p= 0.03). MST was 7.4 and 8.3 months for men ≥60 and <60 years old respectively (NS). In E4599 the age <60 by bevacizumab treatment interaction was statistically significant (p= 0.03) for women (younger had greater benefit), with no age effect in men. Conclusions: In this unplanned, exploratory subgroup analysis of advanced stage NSCLC ECOG trials, women ≥60 years old treated with chemotherapy live longer than men and younger women. In contrast, bevacizumab survival benefit was more pronounced in men of any age and in younger women on E4599.

KW - Age/sex interactions

KW - Bevacizumab

KW - Chemotherapy

KW - NSCLC

KW - Prognostic factors

KW - Sex/gender differences

UR - http://www.scopus.com/inward/record.url?scp=84862815339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862815339&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2011.12.006

DO - 10.1016/j.lungcan.2011.12.006

M3 - Article

C2 - 22266041

AN - SCOPUS:84862815339

SN - 0169-5002

VL - 76

SP - 410

EP - 415

JO - Lung Cancer

JF - Lung Cancer

IS - 3

ER -

Differential effect of age on survival in advanced NSCLC in women versus men: Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this